Expresión de metaloproteasa de matriz 9 en el cáncer de próstata: Experiencia preliminar

Rodríguez, Iván González; Fresno, Manuel Rivas del; Ugarteburu, Rodrigo Gil; Arriaga, Patricia González; Cima, Felicitas López; Samoano, Ana Fernández; Fernández, Valentín Muruamendiaraz; García, Isabel Fernández; Pérez-Carral, J.R.; Tardón, Adonina

doi:10.4321/s0004-06142010000200007

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…González Rodrigues et al [ 14 ] found unsatisfactory results when serum MMP-9 was determined by ELISA in 100 patients with indication for prostate biopsy (prospective cohort study). Of these, 32 were diagnosed with PCa with 52% classified with Gleason greater than or equal to 7.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Prognosis of Prostate Cancer from Circulating Matrix Metalloproteinases and Inhibitors

El-Chaer

Moraes

Nóbrega

2018

Journal of Aging Research

View full text Add to dashboard Cite

Although prostate cancer (PCa) is the sixth most common type of neoplasm in the world and the second in prevalence among men (10% of all cases), there is shortage of studies focused on primary prevention of the disorder as well as little understanding on its pathophysiology. Currently, the PCa screening tools are the prostate specific antigen (PSA) dosage conjugated to rectal examination and confirmed by prostate biopsy. Despite the name, the PSA presents reduced specificity, being necessary the identification of new biomarkers that allow an earlier and more precise diagnosis and even better prognosis. Several studies have associated matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) to PCa tumorigenesis and metastasis. Most of the studies so far have been carried out by investigating in situ expression of the metalloproteinases, either by transcriptional measures or by immunohistochemistry with biopsy or postoperative tissue. Investigations in human plasma and serum are scarce, and a bibliographical search resulted in 17 studies which are presented and interpreted herein. This narrative review discusses their settings and findings along with aspects related to circulating metalloproteinases as potential biomarkers for diagnosis or prognosis of the prostatic malignancy, expressing the authors' reticent view on their applicability due to the poor quality of evidence available.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnosis and Prognosis of Prostate Cancer from Circulating Matrix Metalloproteinases and Inhibitors

El-Chaer

Moraes

Nóbrega

2018

Journal of Aging Research

View full text Add to dashboard Cite

show abstract

Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival

Özden

Saygin

Uzunaslan

et al. 2013

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Analysis of Matrix Metalloproteinase-1 Gene Polymorphisms and Expression in Benign and Malignant Breast Tumors

Zhou

Brinckerhoff

Lubert

et al. 2011

Cancer Investigation

View full text Add to dashboard Cite

A guanine insertion polymorphism in matrix metalloproteinase-1 promoter (MMP-1 2G) is linked to early onset and aggressiveness in cancer. We determined the role of MMP-1 2G on the level of MMP-1 expression and breast cancer severity in benign breast disease, atypical hyperplasia, invasive and non invasive (in situ) breast cancer. We observed no significant difference in genotype distribution among the different breast disease groups. However, the level of MMP-1 expression was significantly higher in atypical ductal hyperplasia compared to benign breast disease; and in invasive breast cancer compared to in situ breast cancer. MMP-1 2G insertion polymorphism in the invasive group also correlated significantly with the expression of MMP-1 and breast cancer prognostic markers HER2 and P53.

show abstract

Expresión de metaloproteasa de matriz 9 en el cáncer de próstata: Experiencia preliminar

Abstract: Resumen.-OBJETIVO: Estudiar la validez de la metaloproteasa 9

Cited by 3 publications

References 12 publications

Diagnosis and Prognosis of Prostate Cancer from Circulating Matrix Metalloproteinases and Inhibitors

Diagnosis and Prognosis of Prostate Cancer from Circulating Matrix Metalloproteinases and Inhibitors

Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival

Analysis of Matrix Metalloproteinase-1 Gene Polymorphisms and Expression in Benign and Malignant Breast Tumors

Contact Info

Product

Resources

About